Navigation Links
OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
Date:5/11/2009

BOTHELL, WA and VANCOUVER, May 11 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that final survival data from a randomized Phase 2 trial evaluating OGX-011 in combination with docetaxel versus docetaxel alone as first-line chemotherapy in patients with metastatic castration-resistant prostate cancer will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. In addition, Phase 1 clinical data evaluating OncoGenex' second product candidate, OGX-427, will also be featured in an oral presentation at ASCO.

Abstracts will be made available to the public online on ASCO's website, www.ASCO.org, on Thursday, May 14 at 6:00 p.m. (EDT).

The oral presentations are scheduled for Saturday, May 30 at the ASCO meeting in Orlando, Florida. These formal presentations will also include new data that has been updated since abstracts were submitted to ASCO.

Abstract Presentation Information

    Title:    Mature results of a randomized phase II study of OGX-011 in
              combination with docetaxel/prednisone versus
              docetaxel/prednisone in patients with metastatic castration
              resistant prostate cancer
    Authors:  K. N. Chi, S. J. Hotte, E. Yu, D. Tu, B. Eigl, I. Tannock,
              F. Saad, S. North, J. Powers, E. Eisenhauer, National Cancer
              Institute of Canada Clinical Trials Group
    Date:     4:30 p.m. - 4:45 p.m. EDT, Saturday, May 30, 2009
    Location: Level 3, Chapin Theatre, W320, Orange County Convention Center
    Abstract: # 5012

    Title:    OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO),
              against HSP27: Results of a first-in-human trial
    Authors:  S. J. Hotte, E. Y. Yu, H. W. Hirte, C. S. H
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Reports First Quarter Financial Results
2. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
3. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
4. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
5. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
6. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
7. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
8. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
9. OncoGenex Reports Third Quarter Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
11. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of ... Report" report to their offering. This report ... US$ Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... La Jolla, CA (PRWEB) August 19, 2014 ... the toll Parkinson’s disease can take on an individual. ... tremoring extremities, decreased facial expression, problems swallowing and severe ... due to the dying off of dopamine producing neurons ... retain themselves from a disease that slowly and progressively ...
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... YORK, Feb. 23 NeoStem, Inc. (NYSE Alternext ... processing and long-term storage of adult stem cells ... signed a license agreement to obtain the exclusive ... applications for cosmetic facial and body procedures and ...
... Pa. and SHANGHAI, Feb. 23 Frontage Laboratories ... bioanalytical, pre-clinical, clinical and drug development services to ... has expanded its research and development agreement with ... Beijing Pharmaceutical Group ("Beijing Pharma"), to accelerate Beijing ...
... (Amex: ETC ) ("ETC" or the "Company") ... equipped to satisfy the requirements of Electronic Medical Records ... University on January 8, 2009, then President-Elect Barack ... care while lowering its costs, we will make the ...
Cached Biology Technology:NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 2NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 3Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 2Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 3Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 4Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 2Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 3Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 4
(Date:8/20/2014)... -- The second annual Biometrics UnPlugged Executive Summit, set ... on September 15, 2014, will feature ... Strategy at Samsung, and Philippe de Raet, Vice President, ... year,s event is Mobility at the Crossroads of ... Mobility at the Crossroads of Commerce & Privacy ...
(Date:8/19/2014)... release is available in German . ... inherently intermittent energy sources. If a large amount of electricity ... future, excess energy will have to be stored during productive ... existing storage capacities are far from adequate for the purpose. ... One important focus lies on battery systems that used to ...
(Date:8/19/2014)... retail seafood counters in 10 different states show ... to unexpectedly high levels of mercury, a harmful ... fish of the same species, but from a ... according to new research by University of Hawai,i ... is essential to allow consumers to choose sustainable ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... Aug. 20, 2012 With concerns about the possible health ... Horizon disaster still fresh in mind, scientists today described ... up oil slicks and keeps oil from sticking to the ... dispersant is used in common food products like peanut butter, ...
... MDBX) ( www.medboxinc.com ) Medbox, Inc. released ... of over $820,000 for the three-month period ending June 30. ... the year, and receivables jumped to an impressive 1.1 million. ... services and the sales of their proprietary prescription medicine dispensing ...
... wasps ( Polistes dominula ) advertise the size of their ... in BioMed Central,s open access journal Frontiers in Zoology ... Aposematism is used by many different animals to warn ... form of distinctive colouration or patterns which predators quickly learn ...
Cached Biology News:New oil spill dispersant made from ingredients in peanut butter, chocolate, ice cream 2Medbox, Inc. Releases 2nd Quarter Financials 2
... unique combination of Coulter volume and ... and accurate cell counting. This flow ... UV, allowing flexible fluorochrome selection for ... only achievable with larger, more expensive ...
... novel procedure for the uniform amplification and ... DNA from small samples. This method has ... highly reproducible amplification and labeling procedure for ... Mini Kit module (QIAGEN) and a ULS ...
... Protein/antibody delivery using PULSin may be ... For example, unlike traditional transfection, with PULSin ... the level and time course of proteins ... may provide more information than traditional RNA ...
... is an innovative reagent for highly efficient ... of living cells. Unlike DNA transfection, with ... amount and timing of exogenous proteins in ... can now be studied. Real time ...
Biology Products: